LITTLE KNOWN FACTS ABOUT MBO128.

Emily Bodnar’s ranking relies over the anticipation of major milestones for Agenus in the approaching year, specially the potential filing of the Biologics License Software (BLA) for their lead drug applicant, botensilimab (bot). Agenus has dosed over 900 patients with bot across many solid tumors, showing a determination to extensive clinical an